Cardiac resynchronization reduced death and hospitalization in heart failure and cardiac dyssynchrony

Morillo, Carlos A.
September 2005
ACP Journal Club;Sep/Oct2005, Vol. 143 Issue 2, p29
Academic Journal
The article presents an answer to a clinical question related to the effect of cardiac resynchronization on morbidity and mortality in heart failure (HF). In patients with heart failure and cardiac dyssynchrony, cardiac resynchronization reduced death and hospitalization for major cardiovascular events. Today, standard therapy of HF includes more than 3 medications, such as angiotensin-converting enzyme inhibitors, beta-blockers and diuretics. Pharmacologic therapy has tackled most of the pathophysiologic mechanisms of HF.


Related Articles

  • Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. Hippisley-Cox, Julia; Coupland, Carol // BMJ: British Medical Journal (International Edition);5/7/2005, Vol. 330 Issue 7499, p1059 

    Objective To determine the effect of combinations of statins, aspirin, β blockers, and angiotensin converting enzyme inhibitors in the secondary prevention of all cause mortality in patients with ischaemic heart disease. Design Open prospective cohort study with nested case-control analysis....

  • Recent Advances in Pharmacotherapy for Heart Failure: Future Directions. Balakumar, Pitchai; Singh, Manjeet // Trends in Medical Research;2007, Vol. 2 Issue 2, p61 

    Heart failure is a significant clinical challenge associated with high morbidity, mortality and economic burden in developing countries and the prevalence of chronic heart failure is continuously increasing. Heart failure is characterized by exercise intolerance, fatigability, dyspnea and volume...

  • Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Nakata, Tomoaki; Wakabayashi, Takeru; Kyuma, Michifumi; Takahashi, Toru; Tsuchihashi, Kazufumi; Shimamoto, Kazuaki // European Journal of Nuclear Medicine & Molecular Imaging;Feb2005, Vol. 32 Issue 2, p186 

    Purpose: Although the benefits of treatment with angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are well known, no method has as yet been established to predict the efficacy of drug therapy. This study tested whether cardiac 123I-metaiodobenzylguanidine (MIBG) activity is of...

  • Is losartan superior to captopril in reducing all-cause mortality in elderly patients with symptomatic heart failure? Trojian, Thomas H.; Jackson, Eric A. // Journal of Family Practice;Aug2000, Vol. 49 Issue 8, p759 

    This article discusses research done to compare the effects of losartan and captopril on the mortality of patients with symptomatic heart failure. It refers to a study by B. Pitt and colleagues in a 2000 issue of "Lancet." A comparison of the efficacy of Angiotension II type 1 receptor blockers...

  • Candesartan reduces cardiovascular death in CHF patients on ACE inhibitor.  // Journal of Family Practice;Feb2004, Vol. 53 Issue 2, p93 

    This article focuses on a study regarding the addition of candesartan to an angiotensin-converting enzyme (ACE) inhibitor and other treatment reduces cardiovascular death and hospital admissions of patients with congestive heart failure (CHF). As in studies conducted with valsartan, candesartan...

  • Dual Blockade of the Renin–Angiotensin–Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. Bomback, Andrew S.; Toto, Robert // American Journal of Hypertension;Oct2009, Vol. 22 Issue 10, p1032 

    The renin–angiotensin–aldosterone system (RAAS), an important regulator of blood pressure as well as fluid and electrolyte balance, plays an important role in the pathophysiology of cardiovascular and kidney diseases. Blockade of the RAAS with angiotensin-converting enzyme...

  • Evidently…. Lehman, Richard // Evidence Based Medicine;Apr2009, Vol. 14 Issue 2, p39 

    The article focuses on the medication of angiotensin-coverting enzyme (ACE) inhibitors in decreasing the mortality of the people due to health failure in Great Britain. Clinicians note that the drug reduces high mortality rate cause by heart failures. They reveal that ACE inhibitors reduce the...

  • Ask the Experts. Reigle, Juanita // Critical Care Nurse;Dec2004, Vol. 24 Issue 6, p67 

    Compares the effectivity of angiotensin-receptor blockers (ARB) and angiotensin-converting enzyme (ACE) inhibitors in treating heart failure. Effect of ACE inhibitors on the mortality and morbidity in patients with chronic heart failure and left ventricle systolic dysfunction; Complications...

  • β‐blockers in left ventricular systolic dysfunction—from evidence to practice. BANDYOPADHYAY, SYAMASIS; O'MAHONY, M. SINEAD // Age & Ageing;Jan2002, Vol. 31 Issue 1, p23 

    Five percent of all hospital medical admissions are patients with heart failure. The incidence is about one new case per 1000 of the general population per year, increasing to >10 per 1000 in those aged 85 years. Although the evidence that β‐blockers reduce mortality by about 36%...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics